Detalles de la búsqueda
1.
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Cancer Immunol Immunother
; 68(11): 1901-1907, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31690955
2.
TGFß-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
J Immunother Cancer
; 10(12)2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600556
3.
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
J Immunother Cancer
; 10(10)2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36316062
4.
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Front Oncol
; 12: 1023015, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36483037
5.
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Oncoimmunology
; 11(1): 2026020, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35111385
6.
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFß-expressing cancer cells in a TGFß-dependent manner.
Cell Mol Immunol
; 18(2): 415-426, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33408343
7.
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 27(12): 2212-2223, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887574
8.
Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
Cancer Immunol Res
; 9(11): 1316-1326, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34518197
9.
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.
Front Oncol
; 11: 637420, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33718228
10.
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.
Oncoimmunology
; 10(1): 1975889, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-38283034
11.
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Oncoimmunology
; 9(1): 1771142, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32923127
12.
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 28(4): 871, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35260843
Resultados
1 -
12
de 12
1
Próxima >
>>